

Contents available at ScienceDirect

Diabetes Research and Clinical Practice

journal homepage: www.elsevier.com/locate/diabres





Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?



Zahra N. Sohani a,b,*, Ling Lic, Xin Sunc

- ^a Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
- ^b Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON L8S 4L8, Canada
- ^c Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

ARTICLEINFO

Article history:
Received 17 February 2016
Received in revised form
21 March 2016
Accepted 16 April 2016
Available online 26 April 2016

Keywords:
Incretin-therapy
Acute pancreatitis
Meta-analysis
Cardiovascular disease

ABSTRACT

Incretin-based therapies are normally prescribed to individuals with type 2 diabetes but has recently come under scrutiny due to the possibility of associated pancreatitis. A 2014 systematic review published in the BMJ found no increase risk of acute pancreatitis in adults with type 2 diabetes, as partly evident from the meta-analysis of RCTs (OR = 1.11, 95% CI 0.57–2.17). By contrast, a second meta-analysis added 3 large outcome trials in patients with previous cardiovascular disease to the previous 55 RCTs from Li et al. and showed an increased risk in acute pancreatitis. While the discrepancy in result may be due to better quality large trials, as the authors suggest, it is likely that since the large outcome trials investigated patients with cardiovascular disease, the increased risk is present only in this group.

© 2016 Elsevier Ireland Ltd. All rights reserved.

Incretin-based therapies are prescribed to individuals with type 2 diabetes owing to good glucose-lowering effects, weight neutrality, and a reduced risk of hypoglycemia [1,2]. But use of incretin-based therapies has come under scrutiny due to a possible association with pancreatitis. A 2014 systematic review published in the BMJ investigated this putative effect with 55 randomized control trials (RCTs), typically phase III, and 5 observational studies [3]. The authors concluded that incretin-therapies do not increase risk of acute pancreatitis in adults with type 2 diabetes, as partly evident from the meta-analysis of RCTs (OR = 1.11, 95% CI 0.57–2.17).

Following publication of these results, a subsequent metaanalysis of RCTs by Roshanov and Dennis [4] added 3 large outcome trials to the previous 55 RCTs from Li et al. Addition of these 3 trials showed an increased risk of acute pancreatitis from incretin-therapies (OR = 1.54, 95% CI 1.07–2.21) [4]. With the 3 trials alone, the results demonstrated an even higher risk (OR = 1.76, 95% CI 1.14–2.72). A presentation by R. Holman at World Diabetes Congress 2015 was consistent with these results [5]. To explain the apparent differences in results, Roshanov and Dennis stated that larger trials likely overcome biases that plague meta-analyses of smaller studies. However, there may be other more plausible explanations.

Notably, there are differences in the populations studied and duration of follow-up between the 3 large outcome trials and RCTs included in Li et al. The 3 large-outcome trials focus on patients with cardiovascular co-morbidities. Specifically, patients in the SAVOR-TIMI 53 trial [6] had either a history of established cardiovascular disease (CVD) or multiple risk factors for vascular disease. Similarly, the EXAMINE trial [7]

^{*} Corresponding author at: Clinical Epidemiology & Biostatistics, McMaster University, Rm. 3500, 1280 Main St. West, Hamilton, ON L8S 4K1, Canada.

E-mail address: sohaniz@mcmaster.ca (Z.N. Sohani). http://dx.doi.org/10.1016/j.diabres.2016.04.031




Fig. 1 - Forest plot of all 59 studies investigating effect of incretin-therapy on acute pancreatitis, with subgroups.

Download English Version:

https://daneshyari.com/en/article/5898763

Download Persian Version:

https://daneshyari.com/article/5898763

<u>Daneshyari.com</u>